The Journal of Pediatrics
Volume 153, Issue 4 , Pages 547-553.e3 , October 2008

Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus

  • H. Peter Chase, MD

      Affiliations

    • Barbara Davis Center, University of Colorado, Aurora, CO
    • Corresponding Author InformationReprint requests: Dr H. Peter Chase, Barbara Davis Center, University of Colorado, Mail Stop A140, PO Box 6511, Aurora, CO 80045-6511
    • ,
  • Silva Arslanian, MD

      Affiliations

    • Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Neil H. White, MD, CDE

      Affiliations

    • Department of Pediatrics, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, MO
    • ,
  • William V. Tamborlane, MD

      Affiliations

    • Department of Pediatrics and the Yale Center for Clinical Investigation, Yale University School of Medicine, New Haven, CT

Received 3 August 2007 ,Revised 2 April 2008 ,Accepted 24 April 2008.

References 

  1. Centers for Disease Control and Prevention. National diabetes fact sheet: United States, 2005 (General information). http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdfAccessed July 25, 2007
  2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  3. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125:177–188
  4. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254–2264
  5. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23:813–819
  6. Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabetes Med. 2006;23:285–292
  7. Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes therapy in children. Pediatr Clin North Am. 2005;52:1705–1733
  8. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15:369–376
  9. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G Insulin Glargine 4014 Study Investigators. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554–559
  10. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci. 2004;328:274–280
  11. Hershon KS, Blevins TC, Mayo CA, Rosskamp R. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004;10:10–17
  12. Riddle MC, Rosenstock J, Gerich J Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086

 Supported by the sanofi-aventis US Group. Chase and White have served on the sanofi-aventis US Medical Advisory Board. Arslanian has received research grant support from and has served on the sanofi-aventis US Advisory Board. Tamborlane has served on the sanofi-aventis US and Novo Nordisk Advisory Boards. The authors had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

PII: S0022-3476(08)00369-7

doi: 10.1016/j.jpeds.2008.04.063

The Journal of Pediatrics
Volume 153, Issue 4 , Pages 547-553.e3 , October 2008

Article Tools

* Image Usage & Resolution